Sergei Petukhov

Sergei Petukhov is a Managing Director at the AMR Action Fund in Boston, Massachusetts, a venture capital initiative backed by major entities like Pfizer, GSK, Novartis, the Wellcome Trust, and the World Health Organization. Managing approximately $1 billion in committed capital, he oversees investments in clinical stage biotechnology companies developing novel therapeutics to combat antimicrobial resistance. In this capacity, Petukhov recently participated in a $106.5 million equity round for Vedanta Biosciences and a $24 million Series B for Adaptive Phage Therapeutics. His broader portfolio oversight includes clinical developers like Venatorx Pharmaceuticals and BioVersys, supporting the fund's goal of bringing two to four new antibiotics to market by 2030. Prior to his current position, he built expertise across animal health and biotechnology ventures through leadership roles at Khepri Animal Health, Ludicrous Ventures, and Metallomix Inc.